Introduction
There is growing evidence that the vitamin D-endocrine system is important not only in the regulation of bone and mineral metabolism but in modulation of other systems as well. As will become evident, this is particularly true with regard to 1,25-dihydroxyvitamin D [1, 25(OH) 2D]'.
Metabolism of vitamin D
The metabolism of vitamin D is outlined schematically in Fig. 1 . Dietary vitamin D2 (irradiated ergosterol) is absorbed in the proximal small intestine via the intestinal lymphatics; this process requires bile acids (1) . Vitamin D3 is produced in the skin from 7-dehydrocholesterol. Previtamin D3 is synthesized photochemically from 7-dehydrocholesterol and over a period of several days undergoes a temperaturedependent isomerization to vitamin D3 (2) . The vitamin is selectively removed by way of the dermal capillaries by vitamin D-binding protein, which has a high affinity for the vitamin. Because vitamin D-binding protein has a low affinity for previtamin D3, this (6) . Upon oxidative cleavage of the side chain, 1,25(OH)2D forms a C-23 carboxylic acid, calcitroic acid (7), which is biologically inactive (8) . Production of calcitroic acid in target tissues may be an important mechanism for inactivation of the biologically potent 1,25(OH)2D. In addition, 1,25(OH)2D undergoes an enterohepatic circulation, as shown in rat (9) and humans (10) .
Regulation of vitamin D metabolism
There is evidence in animal studies that 25-hydroxylation of vitamin D is inhibited by vitamin D (1 1), , and 1,25(OH)2D (12) , and in clinical studies that inhibition 1 [1] [2] [3] [4] [5] [6] is produced by vitamin D (13) and 1,25(OH)2D3 (14) .
Whether 25-OHD plays a physiologic role in regulating its own synthesis has not been established. Inhibition of 25-hydroxylation by vitamin D seems to be a relatively ineffective control mechanism in view of the fact that marked increases in circulating 25-OHD are responsible for the abnormal mineral metabolism in vitamin D intoxication (15) . In contrast, feedback regulation of 25-OHD production by 1,25(OH)2D appears to be effective (Fig. 1) . In small but pharmacologic doses, 1,25(OH)2D3 completely inhibits the increase in serum 25-OHD produced by vitamin D challenge in normal subjects (14) , and serum 25-OHD may be reduced in a number of diseases in which serum 1,25(OH)2D is increased including obesity (16) , vitamin Ddependent rickets type 11 (17) , sarcoidosis (18) , hyperphosphatemic tumoral calcinosis (19) , and tuberculosis (Bell, N. H., unpublished observations). Further, the renal production of 1 ,25(OH)2D in normal children is regulated loosely (20) . As a result, vitamin D challenge produces modest increments in serum 1,25(OH)2D that prevent more substantial increases in serum 25-OHD. Feedback regulation of hepatic production of'the precursor 25-OHD by 1,25(OH)2D, therefore, serves to prevent abnormal increases in circulating 1,25(OH)2D in normal children in whom 1,25(OH)2D production is regulated loosely. The mechanism by which the hepatic production of 25-OHD is modulated by 1,25(OH)2 is unknown. It does not seem to be a receptor-mediated event since receptors for 1 ,25(OH)2D have not been shown in hepatic tissue (21) .
Parathyroid hormone (PTH) is the principal regulator of the renal synthesis of 1,25(OH)2D. Serum 1,25(OH)2D is increased in primary hyperparathyroidism and is reduced in hypoparathyroidism (22, 23) . Circulating 1,25(OH)2D is increased by administration of parathyroid extract in normal subjects and in patients with hypoparathyroidism (23) . The primacy ofPTH in the regulation of synthesis of 1 ,25(OH)2D is also well documented by both in vivo and in vitro studies using a wide variety of laboratory animals (21, (24) (25) (26) .
In intact animals (27) and in normal adults (18, 20) , the renal production of 1, 25 (30, 31) , and diminished increase in circulating 1,25(OH)2D in response to PTH as compared with normal subjects (32), tumoral calcinosis is characterized by hyperphosphatemia, impaired renal excretion of phosphate and increased serum 1 ,25(OH)2D (19) . The disorders seem to be mirror images of each other. It is likely that elucidation of the mechanisms for abnormal phosphate transport in these two diseases will lead to a better understanding of the biochemical events concerning regulation of 1,25(OH)2D production by phosphate.
A second major regulator of the renal production of 1,25(OH)2D is the vitamin D status of the animal or tissue or 1,25(OH)2D itself ( Fig. 1 ). In the vitamin D-deficient state, renal synthesis of 1,25(OH)2D is maximal, and synthesis is inhibited by addition of 1,25(OH)2D (24, 33, 34) . In vitamin D-replete chicks, both basal and PTH-stimulated renal la-hydroxylase activity are diminished (35) . In contrast, basal and PTH-stimulated activities increase with deprivation of vitamin D, and basal renal 25-hydroxyvitamin D-la-hydroxylase varies inversely with serum 1,25(OH)2D (35) . These findings provide evidence that 1,25(OH)2D modulates its own synthesis both in the basal state and in response to PTH.
Parathyroid hormone inhibits the renal synthesis of 24,25(OH)2D (24, 36) , and 25-hydroxyvitamin D-24-hydroxylase activity is enhanced by 1,25(OH)2D (33, 34 (43) . The mass spectrum of the putative 1,25(OH)2D produced by sarcoid tissue in vitro was confirmed (44) . Hypercalcemia associated with abnormal elevation of serum 1,25(OH)2D was described in tuberculosis (45, 46) , lymphoma (47, 48) , disseminated candidiasis (49) , and silicon-induced granuloma (50) . Modest impairment in the regulation of circulating 1,25(OH)2D in response to vitamin D challenge is present in patients with active pulmonary tuberculosis and normal calcium metabolism (45) . In view of the demonstration of synthesis of 1,25(OH)2D by granulomatous tissue in sarcoid (42) (43) (44) , it is likely but not established that the production of 1,25(OH)2D in these diseases is also extrarenal.
Production of 1,25(OH)2D by rat placenta (51), human decidua (52) , chick calvarial cells (53) , and human bone and osteosarcoma cells (54) (61) . These results are consistent with the hypothesis that estrogen deficiency in postmenopausal women increases the sensitivity of the skeleton to PTH (58, 61) . The ensuing decline in serum PTH is followed by decreases in the renal production of 1,25(OH)2D and intestinal absorption of calcium and to increases in urinary calcium resulting from diminished tubular reabsorption (58, 61) . Estrogen replacement decreases the sensitivity of the skeleton to PTH, increases serum PTH, and reverses the changes in intestinal absorption and renal excretion of calcium.
Increased strain on the skeleton produced by obesity also seems to modify the skeletal response to PTH. Obesity is associated with secondary hyperparathyroidism, which is reversible with weight loss (62) . Moreover, the decline in serum immunoreactive PTH varies in proportion to the amount of weight lost. In ongoing studies, we found that urinary cAMP is increased in obese white subjects and correlates with ideal body weight (63 (65) . We found biochemical changes in normal black nonobese subjects similar to those described above in obese white individuals (67) . The increased skeletal mass in blacks is therefore attributed to alteration of the vitamin D-endocrine system and the reduced urinary calcium to enhanced tubular reabsorption caused by secondary hyperparathyroidism (67 (82) , and resorb devitalized adult and fetal human bone (83). 1,25(OH)2D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into multinucleated macrophage-like cells that produce bone resorption (84). Cell maturation in response to 1,25(OH)2D is associated with reversible reduction in the c-myc onchogen (85) . In mice, vitamin D-deficiency produces abnormalities in both bone matrix and in peripheral monocytes, which diminish their attachment to each other to initiate the resorptive process (86) . Further, the attachment of rat peritoneal macrophages to bone was shown to be mediated by saccharides (87). Finally, high dose 1,25(0H)2D3 activated both osteoclasts and peripheral monocytes to produce bone resorption in a patient with malignant osteopetrosis, a disease characterized by impaired osteoclast function (88 (91) and spermidine N'-acetyltransferase (92) in the chick intestine and alkaline phosphatase (93, 94) and Gla protein by bone and rat osteosarcoma cells (95, 96), which have many of the features of osteoblasts, and by human bone cells (97) .
The receptor for 1,25(OH)2D from chick intestine has been purified by two laboratories and has been shown to have a molecular weight of 64,000 D (98) and 67,000 D (99) . Antibodies obtained from the rat and from hybridomas demonstrated the presence of the receptor in intestinal tissue from fish, frog, chick, and rat and in cultured cells from a variety of tissues including human breast and intestine (100) . These results provide evidence for evolutionary conservation of the biochemical structure of the receptor.
The disease vitamin D-dependent rickets type II, which occurs in humans (101, 102) , and in marmoset, a new world monkey (103) (107) . In view of these findings, it is likely that structural abnormalities in the receptor may account for the defective response of target organs to 1,25(OH)2D.
Determining the structure of the 1,25(OH)2D receptor in normal and disease states would be of great importance and could be accomplished either by direct peptide sequencing of the purified receptor or by determination of the gene sequence of the receptor through recombinant DNA technology. The latter method would be quite difficult technically in view of the fact that the receptor represents such a small fraction of the protein synthesized by the cell. This approach, therefore, may not be feasible.
Regulation of cell growth and differentiation
The finding of receptors for 1,25(OH)2D in a number of cells and tissues other than those of established target organs, intestine, bone, and kidney (21) indicates that the hormone may have a number of biologic effects in addition to those related to mineral metabolism. Anemia and myelofibrosis are reported in children with vitamin D-deficient rickets and are corrected by vitamin D (108). Infections are also common (109), and leukocytes from such patients show impaired random motility (110) and defective ability to phagocytose bacteria ( 1 1) . Similarly, vitamin D-deficient mice have a depressed inflammatory response, macrophages which show impaired phagocytosis, and macrophages and leukocytes which exhibit defective spontaneous migration (1 12 (81, 121) . 1,25(OH)2D3 inhibits proliferation and suppresses interleukin-2 activity of phytohemagglutinin-stimulated human lymphocytes (122) . Since interleukin-2 is a growth-promoting lymphokine for activated lymphocytes, inhibition oflymphocyte proliferation may be mediated by inhibition of interleukin-2.
Similarly, 1,25(OH)2D inhibits antigen-induced production of interleukin-2 by cloned Ia-restricted T cell hybridomas (123) and proliferation and production of immunoglobulins IgG and IgM by activated human peripheral mononuclear cells (124) . 1,25(OH)2D3 induces maturation of the human monocyte cell line U937, which contains receptors for the hormone (125), and stimulates production of interleukin-l and lymphocyteactivating factor when incubated with a factor from lectinstimulated human T lymphocytes (126) . These results support a role for 1,25(OH)2D in the regulation of the immune system. Conclusions Technological advancements over the past 15 yr in development and application of assays for PTH, vitamin D and its metabolites, and the synthesis and availability of 25 
